(Q42866795)

8 November 2017

title

Pharmacokinetic and pharmacodynamic variation associated with VKORC1 and CYP2C9 polymorphisms in Thai patients taking warfarin (English)

1 reference

8 November 2017

Pharmacokinetic and Pharmacodynamic Variation Associated with VKORC1 and CYP2C9 Polymorphisms in Thai Patients Taking Warfarin (English)

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

29 July 2024

1 reference

1 reference

Alisara Sangviroon

1

1 reference

8 November 2017

Duangchit Panomvana

2

1 reference

8 November 2017

Wichittra Tassaneeyakul

3

1 reference

8 November 2017

Jule Namchaisiri

4

1 reference

8 November 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20930419

29 July 2024

publication date

1 October 2010

1 reference

8 November 2017

2010

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20930419

full work available at URL

29 July 2024

http://api.elsevier.com/content/article/PII:S1347436715300665?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

http://api.elsevier.com/content/article/PII:S1347436715300665?httpAccept=text/plain

29 July 2024

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

Drug Metabolism and Pharmacokinetics

29 July 2024

published in

1 reference

8 November 2017

volume

25

1 reference

8 November 2017

issue

6

1 reference

8 November 2017

page(s)

531-538

1 reference

Thrombosis and the pharmacology of antithrombotic agents

8 November 2017

cites work

2

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy

29 July 2024

3

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

29 July 2024

4

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphism

29 July 2024

6

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

29 July 2024

7

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

Cytochrome P450 polymorphisms are associated with reduced warfarin dose

29 July 2024

8

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

29 July 2024

10

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

29 July 2024

11

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

Association between the CYP2C9 polymorphism and the drug metabolism phenotype

29 July 2024

12

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis

29 July 2024

13

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

29 July 2024

14

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

29 July 2024

15

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

29 July 2024

16

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

29 July 2024

17

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

29 July 2024

18

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

29 July 2024

19

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.

29 July 2024

20

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population

29 July 2024

21

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.

29 July 2024

22

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

CYP2C9 allelic variants: ethnic distribution and functional significance

29 July 2024

23

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

Determination of warfarin enantiomers and hydroxylated metabolites in human blood plasma by liquid chromatography with achiral and chiral separation

29 July 2024

24

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

A rapid genotyping method for the vitamin K epoxide reductase complex subunit 1 (VKORC1) gene

29 July 2024

27

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

Prevalence of CYP2C9 and VKORC1 mutation in patients with valvular heart disease in northern Thailand

29 July 2024

28

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.

29 July 2024

29

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients

29 July 2024

30

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients

29 July 2024

31

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients

29 July 2024

32

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population

29 July 2024

33

1 reference

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RG-059

29 July 2024

Identifiers

1 reference

8 November 2017

1 reference